Share page on LinkedIn

Cardiovascular insights

There is still significant unmet need within select cardiovascular/metabolic (CVM) disorders, despite continuing to be a leading global cause of death.

Mitigating the impact of COVID-19 on cardiovascular trials

Mitigating the impact of COVID-19 on cardiovascular trials

COVID-19 has had a significant impact on the conduct of clinical trials and participants. Participants in cardiovascular (CV) trials typically are older, with underlying CV disease or risk factors such as hypertension and diabetes – a population at higher risk of death from COVID-19 if they contract the virus.

Read the whitepaper
Cardiovascular medical devices

Thriving in Value-Based Healthcare: A guide for cardiovascular medical device manufacturers

In December 2016, the Centers for Medicare & Medicaid Services (CMS) expanded the Bundled Payments for Care Improvement (BPCI) Initiative to include cardiovascular and hip fracture services, taking a major step in the march towards value-based care in the US. How can medical device manufacturers sustain growth and successfully navigate this new model?

Download the whitepaper
Reimagining patient-centric clinical trials with the IoMT

Reimagining patient-centric clinical trials with the IoMT

Follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.

Download the whitepaper

Receive more insights on cardiovascular clinical trials from ICON

Please visit ICON's Preference Centre and select 'Cardiovascular, Metabolic and Circulation' under 'Therapeutic Areas of Interest' to receive new insights on cardiovascular trials.

Receive new insights

Cardiovascular clinical trials services at ICON

ICON has over 25 years' experience conducting cardiovascular trials, with particular emphasis on key cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, and rare diseases.

Read more about ICON's Cardiovascular clinical trials services